Application of nanodiamond in the diagnosis and treatment of neurological diseases
DOI:
https://doi.org/10.54097/hset.v65i.11233Keywords:
Nanodiamond, Neurodegenerative diseases, Blood-brain barrier.Abstract
The blood-brain barrier has long been a barrier to the treatment of neurological diseases in the brain. It protects brain tissues from damage while limiting the access of drugs to the brain for drug delivery, so nanocarriers with smaller particle size are chosen to break the blood-brain barrier. This review summarizes the structural properties of nanodiamond, the interaction mechanism between nanodiamond and blood-brain barrier, and the application of nanodiamond as a carrier in the diagnosis and treatment of neurological diseases, which provides the theoretical basis for the subsequent diagnosis and treatment of neurological diseases.
Downloads
References
Tang, G. F., Zhang, M. R., Liu, Q. Q., Tian, X. M., & Mai, R. R.. (2022). Applications of nanodiamonds in the diagnosis and treatment of neurological diseases. Journal of Nanoparticle Research, 24(3), 1-23.
Yang Zhijun, Peng Mingsheng, Xie Xiande, et al. Assets of Hydrogen in Natural Diamond Structure[J]. Minerals and Geology, 2001, 15(2):141-145.
Wang Zhicheng. Structural properties and application research of nano-diamond [D]. Nanjing University of Science and Technology, 2004.
Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery 1 A qualitative and quantitative characterization of known drug databases. J Comb Chem 1:55–68
Qin Wei, Luo Yong, Luo Yan. Application prospects of drug-loaded nanoparticles in the treatment of central nervous system diseases [J]. Foreign Medicine (Cerebrovascular Diseases Volume), 2004 (11): 821-824.
Ding S, Khan AI, Cai X, Song Y, Lyu Z, Du D, Dutta P, Lin Y (2020) Overcoming blood-brain barrier transport: advances in nanoparticle-based drug delivery strategies. Materials Today (kidlington, England) 37:112–125
Lu W. (2012). Adsorptive-mediated brain delivery systems. Current pharmaceutical biotechnology, 13(12), 2340–2348.
Jain, S., Mishra, V., Singh, P., Dubey, P. K., Saraf, D. K., & Vyas, S. P. (2003). RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. International journal of pharmaceutics, 261(1-2), 43–55.
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X., (2019). Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chemical Society reviews, 48(11), 2967–3014.
Moscariello P, Raabe M, Liu W, Bernhardt S, Qi H, Kaiser U, Wu Y, Weil T, Luhmann HJ, Hedrich J (2019) Unraveling in vivo brain transport of protein-coated fluorescent nanodiamonds. Small 15: e1902992
Maziukiewicz D, Grzeskowiak BF, Coy E, Jurga S, Mrowczynski R (2019) NDs@PDA@ICG conjugates for photothermal therapy of glioblastoma multiforme. Biomimetics (Basel) 4:3
Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA (2019) Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 15:565–581
Thalhammer A, Edgington RJ, Cingolani LA, Schoepfer R, Jackman RB (2010) The use of nanodiamond monolayer coatings to promote the formation of functional neuronal networks. Biomaterials 31:2097–2104
Chen TM, Tian XM, Huang L, Xiao J, Yang GW (2017) Nanodiamonds as pH-switchable oxidation and reduction catalysts with enzyme-like activities for immunoassay and antioxidant applications. Nanoscale 9:15673–15684
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
